Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
BRIEF-Nurix Therapeutics Announces Hart-Scott-Rodino Clearance Of Global Collaboration With Roche To Co-Develop And Co-Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology July 21 (Reuters) - Nurix Therapeutics Inc NRIX.O:
NURIX THERAPEUTICS ANNOUNCES HART-SCOTT-RODINO CLEARANCE OF GLOBAL COLLABORATION WITH ROCHE TO CO-DEVELOP AND CO-COMMERCIALIZE POTENTIAL BEST-IN-CLASS BTK DEGRADER BEXOBRUTIDEG ACROSS MALIGNANT HEMATOLOGY, IMMUNOLOGY AND NEUROLOGY
NURIX THERAPEUTICS - TO RECEIVE $700 MILLION UPFRONT, UP TO $2.30 BILLION IN TOTAL POTENTIAL PAYMENTS
NURIX THERAPEUTICS - DEVELOPMENT COSTS SHARED 40% NURIX, 60% ROCHE; U.S. PROFITS AND LOSSES SPLIT EQUALLY
NURIX THERAPEUTICS - ROCHE TO CO-COMMERCIALIZE BEXOBRUTIDEG IN U.S.; ROCHE COMMERCIALIZES EX-U.S.; NURIX TO RECEIVE ROYALTIES
NURIX THERAPEUTICS - CO AND ROCHE TO JOINTLY ADVANCE BEXOBRUTIDEG IN CLL, B-CELL MALIGNANCIES, MS, AND CSU
Source text: ID:nGNXwTmbn
Further company coverage: NRIX.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis